THU0207 The effect of the use of glucocorticoids on health assessment questionnaire in patients with rheumatoid arthritis in clinical remission –data from kansai consortium for well-being of rheumatic disease patients (answer cohort)-

Background In the treatment of patients with rheumatoid arthritis (RA), glucocorticoids (GCs) with csDMARDs remain an important treatment option given their capacity to increase clinical, structural and functional efficacy. On the other hand, it is reported that GCs usage even at low dosage significantly deteriorated functional capacity in patients with low disease activity state. In these previous study, disease activity and subsequent joint destruction have no small influence on functional disability. Objectives To investigate the effect of the use of glucocorticoids (GCs) in patients with RA who had maintained clinical remission on functional ability. Methods Among 2,649 patients with RA who achieved DAS-ESR Results Characteristics of patients at baseline were as follows (median (IQR), proportion). The age was 61 (48–68) years, female was 70.6%, disease duration was 4.5 (1.7–10.7) years, RF-positive was 64.4%, ACPA-positive was 70%, DAS28-ESR was 2.0 (1.6–2.6), HAQ-DI score was 0.125 (0–0.5). Of the 1,171 patients, 235 (20.1%) patients had been treated with oral GCs when achieving clinical remission. CRP (0.06 (0–0.2) vs 0.03 (0–0.1), p=0.03), MMP-3 (106.1 (73.2–172.8) vs 49.5 (36.5–77.2), p Conclusions The use of GCs in RA patients with sustained remission was the risk factor of progression of HAQ-DI score dose-dependently. Disclosure of Interest None declared